In this article we estimate the annual cost of illness and quality-adjusted life year (QALY) loss in the United States caused by 14 of the 31 major foodborne pathogens reported on by Scallan et al. (Emerg. Infect. Dis. 17:7-15, 2011), based on their incidence estimates of foodborne illness in the United States. These 14 pathogens account for 95% of illnesses and hospitalizations and 98% of deaths due to identifiable pathogens estimated by Scallan et al. We estimate that these 14 pathogens cause $14.0 billion (ranging from $4.4 billion to $33.0 billion) in cost of illness and a loss of 61,000 QALYs (ranging from 19,000 to 145,000 QALYs) per year. Roughly 90% of this loss is caused by five pathogens: nontyphoidal Salmonella enterica ($3.3 billion; 17,000 QALYs), Campylobacter spp. ($1.7 billion; 13,300 QALYs), Listeria monocytogenes ($2.6 billion; 9,400 QALYs), Toxoplasma gondii ($3 billion; 11,000 QALYs), and norovirus ($2 billion; 5,000 QALYs). A companion article attributes losses estimated in this study to the consumption of specific categories of foods. To arrive at these estimates, for each pathogen we create disease outcome trees that characterize the symptoms, severities, durations, outcomes, and likelihoods of health states associated with that pathogen. We then estimate the cost of illness (medical costs, productivity loss, and valuation of premature mortality) for each pathogen. We also estimate QALY loss for each health state associated with a given pathogen, using the EuroQol 5D scale. Construction of disease outcome trees, outcome-specific cost of illness, and EuroQol 5D scoring are described in greater detail in a second companion article.
Quantitative comparison of the public health impact of foodborne pathogens is central to the risk-based approach to food safety called for by the FDA Food Safety Modernization Act and national and international public health bodies (11, 16, (48) (49) (50) (65) (66) (67) . While they are not the only information that is needed to make sound policy decisions about food safety interventions, they are an important input to policy discussions. Summary health measures, such as the annual number of illnesses, hospitalizations, and deaths as estimated by the Centers for Disease Control and Prevention (CDC) (55) , are critical but incomplete measures of disease burden. They usually exclude congenital disease and chronic sequelae and oversimplify disease symptoms, severities, and outcomes. Integrated measures of disease burden such as costs of illness and quality-adjusted life years (QALYs) permit comparison of the burden of diseases with diverse outcomes on a common scale (39, 43) . Cost of illness measures provide a lower-bound estimate of society's willingness to pay (WTP) to prevent disease and are used extensively in policy analysis. QALY metrics use psychometric scales to measure the relative impact of different health states on individuals' comfort and ability to engage in normal activities. QALYs were developed for use in assessing alternative medical treatment options and are increasingly being used in policy analysis.
This article reports new estimates of annual cost of illness and QALY loss in the United States caused by 15 of the 31 pathogens reported by Scallan et al. (55) . The pathogens discussed in this article will be referred to as indicated in parentheses: Campylobacter spp. (Campylobacter), Clostridium perfringens (C. perfringens), Cryptosporidium parvum (Cryptosporidium), Cyclospora cayetanensis (Cyclospora), Escherichia coli O157:H7 (E. coli O157), Shiga toxin-producing E. coli non-O157 (STEC non-O157), Listeria monocytogenes (Listeria), norovirus, nontyphoidal Salmonella enterica (Salmonella), Shigella spp. (Shigella), Toxoplasma gondii (Toxoplasma), Vibrio vulnificus (V. vulnificus), Vibrio parahaemolyticus and other noncholera Vibrio spp. (Vibrio other), and Yersinia enterocolitica (Yersinia). Following the method of Scallan (55) , we estimated cost of illness and QALY loss separately for V. vulnificus, V. parahaemolyticus, and other noncholera Vibrio spp., but in reporting results in this article we combine estimates for V. parahaemolyticus and other noncholera Vibrio spp., hereafter referred to as ''Vibrio other.'' These pathogens account for 95% of illnesses and hospitalizations and 98% of deaths estimated by Scallan et al. (55) . For each pathogen, we create disease outcome trees that characterize the symptoms, severities, durations, outcomes, and likelihoods of health states associated with that pathogen. We estimate the cost of illness (medical costs, productivity loss, and value of premature mortality) and loss of QALYs for each health state associated with a given pathogen, which are then summed. We also estimated upper and lower bounds for the cost of illness and QALY loss associated with each pathogen based on 90% credible intervals for incidence from Scallan et al. (55) . We estimate that these 14 pathogens cause $14.0 billion ($4.4 to $33.0 billion) in cost of illness and a loss of 61,000 (19,397 to 144,974) QALYs per year. Roughly 90% of mean loss is caused by five pathogens: Salmonella, Campylobacter, Listeria, Toxoplasma, and norovirus. A companion article attributes losses estimated in this study to the consumption of specific categories of foods (3).
Prior cost of foodborne illness and QALY loss studies. There is a growing body of research on both the costs of foodborne illness and loss of health-related quality of life, as measured by health-adjusted life year (HALY) metrics such as QALYs and disability-adjusted life years (DALYs). Recently published studies from New Zealand, Canada, Korea, and The Netherlands estimate both HALY loss and cost of illness due to multiple foodborne pathogens (25, 37, 39, 54, 58) .
In the United States, researchers at the U.S. Department of Agriculture Economic Research Service (ERS) have published a series of cost of illness studies over the past 15 years focused on Campylobacter, Salmonella, E. coli O157, Listeria, and other pathogens (5, 12, 17, 18, 56, 62) . Scharff et al. (56) estimate the economic burden of foodborne illnesses in Ohio by combining cost of illness and monetized QALY losses. As part of their study on the use of HALY measure to the health benefits of federal policy, the Institute of Medicine commissioned a case study comparing alternative HALY measures that focused on Bacillus cereus, Cryptosporidium, E. coli O157, and Salmonella (35).
MATERIALS AND METHODS
In this study, we developed 14 pathogen-specific disease outcome trees to partition overall annual cases into severity categories. These pathogens, listed in Table 1 , include all FoodNet pathogens as well as three additional pathogens (C. perfringens, norovirus, and Toxoplasma) that each rank in the top three in the study by Scallan et al. (55) in terms of either annual illnesses, hospitalizations, or deaths. Disease outcome trees are built on estimates from Scallan et al. (55) of the number of annual cases, hospitalizations, and deaths associated with these pathogens, as well as on published literature on the likelihood of other outcomes. The costs and QALY loss of each health outcome are estimated and then summed across all health outcomes to yield separate pathogen-specific totals for cost of illness and for QALY loss and an associated upper and lower bound built on the 90% credible intervals determined by Scallan et al. (55) .
Development of disease outcome trees. Pathogen-specific disease outcome trees characterize the symptoms, severity, duration, and likelihood of health outcomes associated with illness caused by each pathogen. Each tree is divided into severe cases that result in hospitalization, moderate cases that result in physician visits, and self-limiting mild cases that do not require medical attention. For some pathogens, hospitalized cases are further partitioned by severity, treatment, or outcome. Hospitalizations may be followed by death, full recovery, or chronic sequelae.
Disease outcome trees were developed for each pathogen, based on detailed symptom descriptions and likelihoods drawn from empirical data and peer-reviewed literature. Trees for Salmonella, E. coli O157, Listeria, and Campylobacter were based on ERS trees and updated with hospitalization and fatality rates from Scallan (5, 12, 17-19, 55, 62) . New trees were developed for remaining pathogens based on a review of the available scientific literature and published CDC data (55) . Likelihoods of physician visits (moderate cases) were generally based on rates of physician visits from FoodNet population surveys (71), weighted by pathogen-specific rates of bloody and nonbloody diarrhea drawn from outbreaks and clinical data on sporadic cases (1, 6, 13, 15, 26, 36, 42, 44, 51, 52, 71, 72) . When possible, trees are based on U.S. studies, but peer-reviewed studies from other industrialized countries were used when U.S. empirical data were insufficient or unavailable. The tree for congenital toxoplasmosis is based on estimates for The Netherlands (32), with incidence based on CDC estimates (41) .
The duration of each pathogen-specific health state was likewise estimated based on primary data and available literature. For Cryptosporidium, norovirus, Shigella, Toxoplasma, and Yersinia, the average length of hospital stay is drawn from the Nationwide Inpatient Sample (NIS) database for 2001 to 2003, based on International Classification of Diseases, Ninth Revision (ICD-9) codes for primary diagnosis (2) . For mortality and permanent conditions, the duration is the difference between life expectancy of the U.S. population and age at disease onset (Census 2009). Patient age distributions are based upon a number of sources including NIS and FoodNet data from 2001 to 2004 (2, 7-10).
Disease outcome trees include long-term disabilities, chronic conditions, and latent impacts of acute foodborne illness that are not captured by CDC's incidence estimates (55) . These include Guillain-Barré Syndrome (GBS) (Campylobacter) (17), diarrhea relapse (C. parvum), end-stage renal disease (ESRD) (E. coli O157 and STEC non-O157), vision loss (Toxoplasma), and numerous impacts of congenital toxoplasmosis and listeriosis such as stillbirths, neonatal deaths, and lifelong physical and mental disabilities (41) . There are additional long-term health outcomes not included in present estimates, including reactive arthritis and irritable bowel syndrome (24, 40, 46) . Further details on the descriptions and likelihoods of health states within disease outcome trees can be found in the study by Batz et al. (3) .
Cost of illness estimation. Economists generally view individuals' WTP to reduce risk of illness as the theoretically correct measure of the value of protecting health (4, 23, 31) . This is because individuals' WTP reflects how they weigh the benefits from reducing disease risk against competing needs and desires. Harrington and Portney (31) show that WTP to prevent disease can be decomposed into WTP to avoid the disutility of illness, productivity loss, medical expenditures associated with illnesses that do occur, and expenditures on disease prevention. Harrington and Portney (31) and Kenkel (38) show that under assumptions that would generally be expected to hold, cost of illness is a lower bound on WTP to prevent illness. Empirical comparisons find WTP to reduce morbidity risk is 1.6 to 8.0 times larger than cost of illness (23). parahaemolyticus and other noncholera
Vibrio spp.
The availability of empirical estimates limits choice of valuation measures. WTP to reduce mortality risk has been widely studied and used to compute the value of statistical life (VSL) (63, 70) . But few studies have estimated WTP to reduce morbidity associated with foodborne illness (14, 28, 33) . As a result, food safety policy analysis in the United States has historically relied on cost of illness estimates that are limited to costs of medical treatment, productivity losses from days out of work, and varying approaches to mortality valuation. Some studies have attempted to approximate WTP values for morbidity by monetizing QALYs for these health states (56) . A recent Institute of Medicine panel recommended against this practice because of differences in the theoretical basis of each measure and the types of tradeoffs they each elicit (27, 35, 59) . Even if these theoretical concerns are ignored, use of a constant WTP to value QALY loss is not supported by empirical research (20, 29) .
The methods used in this study are generally consistent with ERS cost of illness estimates, with the exception of mortality valuation. Formally, cost of illness for any pathogen can be expressed as follows:
where n is the number of estimated annual cases of disease caused by pathogen p, p i is the probability of health state i occurring, c i is cost of medical treatment, r is the adjusted average population daily wage rate, w i is the number of work days lost, V is the VSL, and m is a binary value that is 1 if i is death or 0 for all morbidity states. Standard practice in federal regulatory impact analyses is to use an age-invariant VSL to value the benefits of reducing risk of death (18) . ERS research annuitizes VSL estimates based on age at death (18) . This study instead follows the U.S. Environmental Protection Agency and U.S. Food and Drug Administration practice of valuing all deaths at a constant VSL and uses an estimate of $7.9 million (in 2009 U.S. dollars) drawn from a meta-analysis of economic studies (53, 63) . ERS also assumes that 60% of neonatal deaths, stillbirths, and miscarriages ''will be replaced by siblings who fully compensate for the earlier loss'' and therefore include only 40% of such losses in cost of illness estimates (5) . In Circular A-4 (68) the White House Office of Management and Budget directs federal agencies to use values for children that are at least as high as for adults unless there is ''specific and compelling evidence to suggest otherwise.'' As there are no known WTP studies for such losses, we value all miscarriages, stillbirths, and neonatal deaths by the same VSL as for all other deaths. Cost of medical treatment includes physician and emergency room visits, hospitalization, outpatient treatment, and long-term care for permanent or chronic conditions, with costs of hospitalization the most significant. The ERS Cost of Illness Calculator estimates for Salmonella, Campylobacter, Listeria, and E. coli O157 were updated to 2009 U.S. dollars following the ERS practice of using medical care-specific consumer price indices (5, 12, 17-19, 61, 62) . For Cryptosporidium, norovirus, Shigella, Toxoplasma, and Yersinia, costs of hospitalization are the means of values from the NIS database for 2001 to 2003, based on matching ICD-9 codes for primary diagnosis (2) . The remaining pathogens did not have sufficient coverage in the NIS, so per-visit hospitalization costs were estimated on the basis of diseases with similar symptoms and severities. Costs per hospitalization for STEC non-O157 disease were assumed to be the same as for E. coli O157, for Cyclospora disease the same as for Cryptosporidium, for C. perfringens disease the same as for norovirus, and for disease caused by Vibrio other the same as for Salmonella. V. vulnificus hospitalization costs were based on those of Listeria adjusted for differences in intensive care unit utilization rates. For all pathogens, hospitalized cases were assumed to have additional medical costs including physician, emergency room, and outpatient services; these were modeled as equivalent to cases of salmonellosis.
Mild and moderate cases of foodborne illness are assumed to have the same daily health care utilization and costs as mild and moderate salmonellosis. Daily costs are multiplied by pathogenspecific illness durations. Because costs of prescription and overthe-counter medication were only 0.2% of total costs estimated by ERS for E. coli O157 and because we lacked sufficient data for other pathogens, such costs are excluded.
Productivity loss is estimated for each health state as the product of days of work lost per case and daily wage rate, adjusted for the employment rate (60, 61) . To remain consistent across pathogens, we use the mean of the age-adjusted daily wage rate and employment rate in ERS estimates for Salmonella, updated to 2009 U.S. dollars (60, 61) . That is, we assume $105.48 in productivity loss per workday lost, based on a daily wage rate of $237.33 and an employment factor of 0.44. Workdays lost are based on health state durations. Following ERS Cost Calculator assumptions for Salmonella, which scale for a 5-day work week and adjust for symptom severity, we assume 0.25 workday lost for each day of mild symptoms, 0.33 workday lost for each day of moderate symptoms, and 0.71 workday (five-sevenths of a week) lost for each day of hospitalization or posthospitalization recovery.
Our estimates include medical costs and productivity losses due to some long-term health outcomes, as discussed above, such as mental disabilities resulting from congenital listeriosis, physical and mental disabilities resulting from Campylobacter-associated GBS, and ESRD following infection with STECs, based mainly on prior studies (5, 12, 17, 18, 62) . We assume that the per-case costs of diarrhea relapse following illness due to Cryptosporidium are equivalent to a mild acute case.
Although we were able to specify health states for congenital toxoplasmosis, we did not find sufficient data or research on medical costs or productivity losses to include it in the analysis. As a result, the cost of illness estimates for Toxoplasma in this study are more conservative, relative to other pathogens, than are the QALY estimates.
QALY scoring and estimation. While economists view WTP as the appropriate measure of the benefits of preventing disease, many in public health circles criticize the measure for implicitly assuming that the existing income distribution is normatively acceptable. Health-adjusted life year measures (HALYs) developed for use in measuring the relative costeffectiveness of alternative clinical treatments are increasingly being used to measure disease burden in a broad array of population health applications (21, 44, 47) . HALYs are built on the principle that health-related quality of life can be measured on a scale from 0 (death) to 1 (perfect health). (Increasingly, negative values are included on this scale to accommodate health states that people feel are ''worse than death'' (57).) For any given health state, HALYs are computed by multiplying this ''preference weight'' by the duration of that health state (in years). HALY loss is measured as the difference between HALYs for an adverse health state and ''baseline'' health without that condition (21) .
Two of the most common HALY measures are DALYs and QALYs (22, 47) . NAS recently recommended use of QALYs rather than DALYs for federal policy analysis principally because QALY preference weights are population based and country specific and therefore better reflect the public's health preferences than DALYs, which rely wholly on expert assessment (35). QALYs can be based on one of several standardized instruments;
we follow the National Academies of Science recommendation to use the EuroQol EQ5D (35).
The EQ5D instrument consists of five health domains, each of which can be scored with a 3-point Likert scale (Table 2 ) (57). Thus, the EQ5D defines 243 (3 5 ) health states, each of which has a unique five-digit descriptor (11111 to 33333). In this study, symptom definitions were developed for each health state in the disease outcome trees based on the clinical literature and then scored along the five domains. Symptom definitions and EQ5D scores were reviewed by medical clinicians experienced with foodborne disease.
The value associated with each five-digit descriptor is estimated on the basis of results from a nationally representative EQ5D survey of the U.S. population (57) . This survey asked individual respondents to describe their current health along each of the five EQ5D domains as well as along a visual analog scale from 0 to 1. Statistical analysis was used to estimate the mean, 0 to 1, preference weight associated with each unique five-digit descriptor. We apply U.S. population-based preference weights estimated by Shaw et al. in 2005 (57) to the five-digit descriptors for each of our estimated health states.
QALY loss for a given pathogen is calculated as follows:
where n is the number of estimated annual cases of disease with that pathogen, p i is the probability of a health state i occurring, d i is the duration of health state i, b i is the preference weight for health state i, and a is defined as the average preference weight for current health across the U.S. population. Durations and probabilities for our QALY loss estimates are drawn from the disease outcome trees described above. Uncertainty analysis. As with any such complex modeling effort, there are numerous sources of uncertainty in our estimates of cost of illness and QALY loss, including both model uncertainty due to assumptions about structural relationships and measurement uncertainty associated with estimation of parameter values. We examined the uncertainty associated with numerous modeling assumptions and parameter values in preliminary sensitivity analyses. We found that the two sources of uncertainty with greatest impact were that associated with incidence estimates, particularly estimates of the number of annual deaths, and that associated with the VSL applied to mortality estimates. We conducted sensitivity analyses on alternative values for the VSL and modeled uncertainty about incidence estimates to estimate a range of annual cost of illness and QALY loss.
To incorporate incidence uncertainty, we created alternate disease outcome trees based on the 90% credible intervals for annual number of illnesses, hospitalizations, and deaths reported by Scallan et al. (55) . That is, for each pathogen, we created a tree that utilized the lower-bound estimates for these values, and we also created a parallel tree using the upper-bound estimates. For these estimates, we also incorporated ranges of values for incidence of Campylobacter-associated GBS (17) and congenital toxoplasmosis (41) .
RESULTS
The primary results from this study are estimates of the annual cost of illness and of QALY loss associated with each of 14 pathogens. Intermediary results include subtotals by disease severity and outcome as well as the estimated number of annual cases for each severity level. Table 1 presents estimates of disease incidence by pathogen, broken down by the number of cases that fall into each of six disease severity categories (mild, moderate, and severe morbidity, mortality due to acute infection, chronic morbidity, and mortality due to chronic sequelae). Listeria and Toxoplasma are partitioned into adult cases and congenital cases. The 14 foodborne pathogens examined in this study impose a total cost of $14.0 billion ($4.4 to $33.0 billion) in a typical year (Table 3 ). Ninety percent of these costs are due to five pathogens: Salmonella ($3.3 billion), Toxoplasma ($3.0 billion), Listeria ($2.6 billion), norovirus ($2.0 billion), and Campylobacter ($1.7 billion). Mortality following acute infection accounts for 78% of total costs. Norovirus is responsible for over 50% of the total costs due to mild and moderate cases of foodborne illness but only 26% of costs due to hospitalized cases and 11% of mortality impacts.
We estimate a loss of 61,000 QALYs (19,000 to 145,000) due to all 14 foodborne pathogens (Table 4 ). Over 90% of QALY loss is due to the same top five pathogens identified in cost of illness comparisons: Salmonella (17,000), Campylobacter (13,000), Toxoplasma (11,000), Listeria (9,000), and norovirus (5,000). Mortality following acute infection causes 73% of total QALY loss. E. coli O157 and other foodborne STECs have been implicated in many high-profile outbreaks. Yet foodborne STECs cause about $280 million in costs of illness and a loss of about 1,700 QALYs annually. These values are significantly below the top five pathogens. Figures 1 and 2 highlight the fact that the same group of five pathogens causes the greatest burden in both QALY loss and cost of illness. Indeed, both metrics roughly cluster pathogens into the same sets of pathogens with high, medium, and low disease burden. The set of top five, middle five, and bottom four pathogens are the same across metrics, though the order differs within these groupings.
Figures 1 and 2 also highlight results from uncertainty analysis on incidence estimates. Rankings based on upper and lower bounds differ slightly from those based on mean estimates, but what is most notable is the size of the ranges on the top-ranked pathogens. The figures show noticeably narrower ranges for Toxoplasma and norovirus than for Salmonella, Campylobacter, and Listeria. Modeling differences in the study by Scallan et al. (55) may contribute to the marked difference in ranges for these pathogens. The last three pathogens are estimated on the basis of multiple years of surveillance data, while Toxoplasma estimates are based on serologic data from the National Health and Nutrition Examination Survey and norovirus estimates are based on annual population surveys.
In sensitivity analysis, we examined alternate VSL values based on the work of Viscusi (69) , ranging from a low value of $1.4 million to a high value of $14.0 million. These VSL values result in a range of total costs of illness due to 14 pathogens of $4.4 to $23.1 billion. The choice of VSL estimate results in significantly different estimates of the cost of illness, but because death itself dominates relative health burden rankings, it has little effect on the relative ranking of pathogens based on cost of illness. Table 5 presents rank correlations for cost of illness, QALY loss, and three primary summary measures of disease incidence due to acute infection. Both cost of illness and QALY loss are heavily driven by mortality. Ranks by QALY loss and by cost of illness are highly correlated (r0 .95). The key result from these correlations is that underlying health outcomes are weighted differently in QALY loss and cost of illness. Cost of illness has a slightly higher correlation with deaths than QALY loss. Hospitalizations have greater influence on QALY loss than on cost of illness. Illnesses that do not cause hospitalizations have less influence on cost of illness than on QALY loss. Differences in pathogen rankings by cost of illness and by QALY loss are due in part to the relative importance of mortality compared to morbidity and to the sensitivity of mortality valuation to age at death. While valuation of mortality constitutes 85% of the costs of illness due to acute disease (ignoring chronic sequelae), it constitutes over 91% of QALY loss. The effect of taking age at death into consideration is seen in comparing mortality impacts by QALY and by cost of illness. Valuation of stillbirths and neonatal deaths due to Listeria and Toxoplasma constitutes about 5% of cost of illness due to mortality but over 10% of QALY loss due to mortality.
Chronic sequelae make up 8% of total costs of illness but 20% of total QALY loss ( Tables 3 and 4 ). In part, this is because we were able to compute QALY loss for disabilities associated with congenital toxoplasmosis, but a larger issue is that QALYs also seem more sensitive than cost of illness to long-term disabilities, particularly for serious complications such as those involving paralysis or chronic pain. For example, GBS is responsible for 56% of the cost of illness due to Campylobacter but for nearly 77% of QALY loss. QALY loss of chronic sequelae as measured by the EQ5D instrument reflects pain, anxiety, and depression, as well as impact on normal activity. Cost of illness estimates include only medical costs and productivity losses, but not disutility of illness. Thus, our cost of illness approach may significantly underestimate the true burden of chronic sequelae.
DISCUSSION
Integrated metrics such as cost of illness or QALY loss enhance basic disease incidence estimates by enabling comprehensive comparisons of diseases with very different patterns of incidence and severity. Such comparisons provide an important part of the information foundation for risk-based approaches to setting food safety policy priorities but do not by themselves indicate how policy priorities should be set. Information on policy effectiveness and cost and concerns about the distribution of health and policy impacts are also important inputs to policy decisions.
A growing number of studies around the world have used cost of illness and QALY loss to value the impact of foodborne illness. The most comprehensive recently published study in the United States estimates cost of illness caused by 27 pathogens in Ohio (56). Scharff et al. (56) estimate cost of illness using monetized QALY loss to account for lost productivity and disutility of illness, which results in significantly higher per-case estimates than found in this study. Applying the per-case estimates from Scharff et al. (56) to CDC incidence estimates (55) results in an estimate of a total cost of illness of $20.8 billion for the 14 pathogens examined here. Substituting wage-based productivity loss estimates for Scharff's monetized QALY losses results in an estimate of $13.1 billion compared with our $14.0 billion estimate. There remain differences in pathogen-specific percase estimates, but these can be explained by the fact that Scharff et al. (56) use older CDC estimates of hospitalization and fatality rates (45), do not include revised ERS estimates of the costs due to GBS (17), do not include congenital toxoplasmosis, and use different assumptions for valuation of lost pregnancies and neonatal deaths due to Listeria.
Estimation of cost of foodborne illness is an ongoing area for research. In particular, there are significant gaps in underlying data and specific needs for statistical analysis. Uncertainty analysis points to the difficulty of comparing relative health impact across pathogens when incidence estimates are based on very different data sources and methodologies. While estimates of DALY loss due to postinfectious reactive arthritis and irritable bowel syndrome have been computed, comparable cost of illness estimates are lacking (24, 39) . Better data on the rates of these and other chronic sequelae associated with specific pathogens are needed, as well as details on medical costs, durations, and outcomes for these conditions. Estimates of WTP to prevent the most important chronic diseases associated with foodborne disease, such as GBS, ESRD, irritable bowel syndrome, and reactive arthritis, could provide a more accurate assessment of the value of preventing foodborne illness. EPA assessments of the benefits of air pollution regulations show the WTP to prevent chronic bronchitis to be 5 to 10% of the WTP to prevent mortality (64) .
Finally, particular attention should be focused on improving estimates of the incidence of foodborne toxoplasmosis and of the percentage that is foodborne and on determining which foodborne pathways are most important. Toxoplasma is the second leading cause of foodborne deaths according to Scallan et al. (55) , which consequently drives its high rankings in our results. Yet, because toxoplasmosis is traditionally associated with cats rather than food, because it generally impacts those with seriously compromised immune systems, and because it can cause disease after long latency periods, it is not typically treated as a major foodborne pathogen by the regulatory agencies. While data may be too uncertain to recommend changes to federal policy, our results do suggest that greater attention in understanding the burden of foodborne toxoplasmosis is warranted.
